Reading patch tests on day 7

Saino, M.; Rivara, Giampiero; Guarrera, Marcella

doi:10.1111/j.1600-0536.1995.tb00794.x

Cited by 22 publications

(13 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In patch tests with a broad panel of allergens, up to 15 % of positive reactions are not detected if there is no subsequent reading after day 3 (15 % ; 13.5 % ; 12.8 % ; 3 % .…”

Section: Duration Of Exposurementioning

confidence: 99%

“…2000 (4 according to OCEBM) ; Madsen & Andersen 2012 (4 according to OCEBM) ; Saino et al. 1995 (4 according to OCEBM) …”

Section: Duration Of Exposurementioning

confidence: 99%

“…In patch tests with a broad panel of allergens, up to 15 [56,57,59] Figure 1 depicts the chronological sequence of patch testing. It is recommended that patch test readings be performed strictly based on morphological criteria (Table 3).…”

Section: Is It Useful To Do a Third Reading (Late Reading) After 7-10mentioning

confidence: 99%

See 2 more Smart Citations

S3 guidelines: Epicutaneous patch testing with contact allergens and drugs – Short version, Part 1

Mahler

Nast

Bauer

et al. 2019

J Deutsche Derma Gesell

View full text Add to dashboard Cite

Summary Epicutaneous patch testing is the diagnostic standard for the detection of allergic contact dermatitis. The present guidelines are aimed at residents and board‐certified physicians in the fields of dermatology and allergology as well as other medical specialties involved in establishing the indication for patch testing and its execution in patients with contact dermatitis and other forms of delayed‐type hypersensitivity. The target audience also includes other health care providers and insurance funds. Based on a systematic literature search and a formal consensus process (S3), the guidelines were developed by dermatologists in collaboration with pediatricians, occupational medicine physicians, nursing staff as well as patient representatives. The systematic methodological approach and appraisal of evidence upon which the recommendations are based are outlined in a separate method report that also contains evidence tables. The guidelines address general aspects of patch testing as well as medicolegal issues. The recommendations given relate to topics such as the indication for patch testing, informed patient consent, as well as the choice of test substances, test chambers and test site, duration of exposure, reading times and interpretation of test reactions. Furthermore, recommendations are provided with respect to endogenous and exogenous factors, specific patient groups (children, pregnant women, immunosuppressed individuals) as well as possible risks and adverse events associated with patch testing using contact allergens. Note: This publication is part 1 of the short version of the S3 guidelines for “Epicutaneous patch testing using contact allergens and drugs” (registry no. 013 – 018; date: March 20, 2019; valid until December 31, 2021). Part 2 of the short version will be published in the next issue. The long version of these guidelines can be accessed at http://www.awmf.org. The method report is available as online publication (https://www.awmf.org/leitlinien/detail/ll/013-018.html) and contains the evidence tables in its appendix.

show abstract

“…In patch tests with a broad panel of allergens, up to 15 % of positive reactions are not detected if there is no subsequent reading after day 3 (15 % ; 13.5 % ; 12.8 % ; 3 % .…”

Section: Duration Of Exposurementioning

confidence: 99%

“…2000 (4 according to OCEBM) ; Madsen & Andersen 2012 (4 according to OCEBM) ; Saino et al. 1995 (4 according to OCEBM) …”

Section: Duration Of Exposurementioning

confidence: 99%

See 1 more Smart Citation

S3 guidelines: Epicutaneous patch testing with contact allergens and drugs – Short version, Part 1

Mahler

Nast

Bauer

et al. 2019

J Deutsche Derma Gesell

View full text Add to dashboard Cite

show abstract

“…Most centres perform patch test readings on D2 to D4. A late patch test reading on D7 in addition to the D3 or D4 reading can identify new positive patch test reactions, ranging from 3% up to 34% in previous studies, which were found to be negative, doubtful or irritant on preceding readings . Multiple studies have reported the importance of an additional late patch test reading, especially for suspected contact allergies to metals, topicals, and corticosteroids.…”

Section: Introductionmentioning

confidence: 99%

New positive patch test reactions on day 7—The additional value of the day 7 patch test reading

et al. 2019

View full text Add to dashboard Cite

Background Not performing a day (D) 7 patch test reading might result in positive patch test reactions being missed. Objectives To investigate the added value of the D7 patch test reading for individual allergens, and to identify patient characteristics and allergen groups associated with new positive D7 reactions. Methods Data from patients patch tested between 2008 and 2018 with the extended European baseline series were analysed. Patch test readings were performed on D3 and D7. Positive reactions were categorized into positive on D3 or new positive on D7. Results A total of 3292 patients were consecutively patch tested with at least 43 allergens of the TRUE Test panels 1 and 2 supplemented with investigator‐loaded allergens. In total, 447 (13.6%) patients showed new positive D7 reactions. In univariable regression analysis, age between 18 and 30 years showed a negative association with new positive D7 reactions. Significantly more D7 positive reactions were seen for topicals (odds ratio [OR] 2.60, 95% confidence interval [CI]: 1.92‐3.51) and corticosteroids (OR 1.87, 95%CI: 1.09‐3.21). No associations were found between sex, atopic dermatitis and occupational dermatitis and a new positive D7 reaction. Conclusion A D7 reading to identify new positive patch test reactions is of added value, especially for topicals and corticosteroids.

show abstract

“…Bis zu 15 % der positiven Reaktionen werden bei Testung eines breiten Panels an Allergenen nicht erfasst, wenn eine Ablesung später als an d3 nicht mehr erfolgt (15 % ; 13,5 % ; 12,8 % ; 3 % .…”

Section: Testort Applikationszeitpunkt Expositionsdauer Und Ablesezunclassified

S3‐Leitlinie: Durchführung des Epikutantests mit Kontaktallergenen und Arzneimitteln – Kurzfassung Teil 1

Mahler

Nast

Bauer

et al. 2019

J Deutsche Derma Gesell

View full text Add to dashboard Cite

Zusammenfassung Der diagnostische Standard zum Nachweis einer bestehenden allergischen Kontaktdermatitis ist der Epikutantest. Die vorliegende Leitlinie richtet sich an Assistenz‐ und Fachärzte der Dermatologie, Allergologie und Ärzte weiterer Fachgruppen in Klinik und Praxis, die an der Indikationsstellung oder Durchführung von Epikutantests bei Patienten mit Kontaktekzemen und weiteren Spättypallergien beteiligt sind, sowie Kooperationspartner der Ärzteschaft (Fachberufe im Gesundheitswesen, Kostenträger). Die Leitlinie zur Durchführung des Epikutantests mit Kontaktallergenen wurde auf der Basis einer systematischen Literatursuche zu definierten Schlüsselfragen evidenzbasiert und im formellen Konsensusverfahren (S3) von Dermatologen unter Einbindung von Pädiatern, Arbeitsmedizinern, Assistenzpersonal und Patientenvertretern erstellt. Bezüglich der methodischen und inhaltlichen Arbeit, auf denen die Empfehlungen basieren, wird auf Methodenbericht und Evidenztabellen verwiesen. Die Leitlinie stellt allgemeine Aspekte der Epikutantestung sowie medizinrechtlicher Aspekte dar. Es werden Empfehlungen gegeben zur Indikationsstellung, Patientenaufklärung, Auswahl von Testsubstanzen und Kammersystemen, Expositionsort, ‐dauer und Ablesezeitpunkten, Interpretation von Testreaktionen, endogenen und exogenen Einflussfaktoren, Testung besonderer Personengruppen (Kinder, Schwangere, Immunsupprimierte) sowie Risiken und unerwünschten Nebenwirkungen bei der Durchführung des Epikutantests mit Kontaktallergenen.

show abstract

Reading patch tests on day 7

Cited by 22 publications

References 5 publications

S3 guidelines: Epicutaneous patch testing with contact allergens and drugs – Short version, Part 1

S3 guidelines: Epicutaneous patch testing with contact allergens and drugs – Short version, Part 1

New positive patch test reactions on day 7—The additional value of the day 7 patch test reading

S3‐Leitlinie: Durchführung des Epikutantests mit Kontaktallergenen und Arzneimitteln – Kurzfassung Teil 1

Contact Info

Product

Resources

About